Black Rock Inc. Actinium Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,708,988 shares of ATNM stock, worth $13.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,708,988

Previous 1,691,914 1.01%

Holding current value

$13.9 Million

Previous $8.59 Million 55.7%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$5.0 - $9.2 $85,370 - $157,080	17,074 Added 1.01%	1,708,988 $13.4 Million
Q4 2023 Feb 13, 2024	SELL	$4.02 - $6.08 $293,387 - $443,730	-72,982 Reduced 4.14%	1,691,914 $8.59 Million
Q3 2023 Nov 13, 2023	BUY	$5.91 - $7.37 $391,395 - $488,085	66,226 Added 3.9%	1,764,896 $10.4 Million
Q2 2023 Aug 11, 2023	BUY	$7.15 - $9.39 $8.23 Million - $10.8 Million	1,151,187 Added 210.27%	1,698,670 $12.6 Million
Q1 2023 May 12, 2023	BUY	$8.51 - $14.26 $553,839 - $928,055	65,081 Added 13.49%	547,483 $5.17 Million

Q4 2022 Feb 13, 2023	BUY	$9.71 - $12.51 $2.23 Million - $2.87 Million	229,548 Added 90.78%	482,402 $5.14 Million
Q3 2022 Nov 14, 2022	BUY	$4.81 - $8.48 $101,192 - $178,402	21,038 Added 9.08%	252,854 $1.87 Million
Q2 2022 Aug 12, 2022	BUY	$4.71 - $7.11 $4,078 - $6,157	866 Added 0.37%	231,816 $1.11 Million
Q1 2022 May 12, 2022	BUY	$4.57 - $6.4 $11,964 - $16,755	2,618 Added 1.15%	230,950 $1.18 Million
Q4 2021 Feb 10, 2022	BUY	$6.01 - $8.8 $54,624 - $79,983	9,089 Added 4.15%	228,332 $1.37 Million
Q3 2021 Nov 09, 2021	SELL	$5.76 - $9.67 $18,944 - $31,804	-3,289 Reduced 1.48%	219,243 $1.94 Million
Q2 2021 Aug 11, 2021	BUY	$7.01 - $8.63 $1.56 Million - $1.92 Million	222,532 New	222,532 $1.76 Million

Others Institutions Holding ATNM

# of Institutions

Shares Held

6.65M

Call Options Held

369K

Put Options Held

148K

View Full List

About Actinium Pharmaceuticals, Inc.

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $205M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

More about ATNM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account